We report a case of pyothorax caused by Nocardia (N.) otitidiscaviarum infection in a 69-year-old man with rheumatoid vasculitis, who was regularly treated with prednisolone in our hospital. Initially, the patient responded poorly to intravenous imipenem/cilastatin (IPM/CS), minocyclin (MINO), and oral trimethoprimsulfamethoxazole (TMP-SMX), but later improved after treatment with levofloxacin (LVFX) and gentamicin sulfate (GM) according to in vitro susceptibility tests. To our knowledge, this is the first description of pyothorax caused by N. otitidiscaviarum infection. It is a rare disease, but recognition of the disease in immunocompromised patients and the prompt initiation of appropriate treatments based on isolation of the pathogen and susceptibility testing can lead to a successful outcome. 
Introduction
Nocardia species are aerobic actinomycetes and common inhabitants of soil. Nocardiosis usually occurs as an opportunistic infection in immunocompromised patients (1) . Recent reports have shown an increase in the incidence of Nocardia spp. infections, probably due to a higher degree of clinical suspicion, the use of more aggressive diagnostic examinations, the increased use of immunosuppressive treatments (corticosteroid, chemotherapeutic agents and immunosuppression for organ transplantations) (2, 3) , and the appearance of the acquired immunodeficiency syndrome (4) . The common site of infection is the lung. However, clinical manifestations are quite variable in each patient ranging from an insidious onset to an acute onset resembling pulmonary infarction (5) . Although all Nocardial infections are increasingly being diagnosed, infection with Nocardia (N.) otitidiscaviarum remains relatively uncommon (6) .
Here, we report the first case of pyothorax caused by N. otitidiscaviarum in an immunosuppressive patient with rheumatoid vasculitis. This case responded poorly to intravenous imipenem/cilastatin (IPM/CS), minocycline (MINO) and trimethoprim-sulfamethoxazole (TMP-SMX). The clinical outcome was favorable after treatment with gentamicin sulfate (GM) and levofloxacin (LVFX).
Case Report
A 69-year-old man was admitted to our hospital because of a 2-week history of fever, cough and left lateral chest pain. He was diagnosed with rheumatoid vasculitis in 1987, and treated with corticosteroid for 17 years in our hospital. His clinical symptoms (polyarthralgia and skin ulcer of the lower limbs) and laboratory data were well controlled by oral prednisolone (10 mg/day) until quite recently. However, glucose intolerance caused by steroid therapy had developed in November 1998. He was treated with voglibose and glimepiride.
On admission, his body temperature was 38.0°C. Coarse crackles were heard on auscultation of the left lower part of the chest, but no cyanosis was observed. Laboratory data on admission are shown in Table 1 . White blood cell (WBC) count was 17,100/ l with marked neutrophilia (93.5%). Creactive protein (CRP) was 21.2 mg/dl. Fasting plasma glucose and hemoglobin A1C was 150 mg/dl and 6.6%, respectively. Sputum and blood culture were negative. Chest roentgenogram revealed massive left-side pleural effusion (Fig. 1A) . Chest CT also showed the presence of fluid encapsulated by an irregularly thickened pleural membrane (Fig.  1B) .
Due to the prolonged use of steroids without prophylaxis, we suspected tuberculous pleuritis or aspergillosis at the time of admission. However, a diagnostic thoracentesis revealed Gram-positive branching rods in the pleural fluid (Fig. 2) . The isolates were identified as N. otitidiscaviarum based on a series of biochemical reactions: 1) Hydolysis of xanthin and hypoxanthin were positive, 2) Hydolysis of casein was negative, and 3) Hydolysis of tyrosine was negative.
Biochemical characteristics of the N. otitidiscaviarum (present isolate) compared with those of N. asteroides and N. brasiliensis are shown in Table 2 . No Mycobacterium, Aspergillus or other microorganisms were found and the result of polymerase chain reaction of Mycobacterium tuberculosis was negative in the fluid. Initially, he was treated with pleural drainage using an intercostal catheter together with intravenous IPM/CS (1.0 g/day), MINO (200 mg/day) and oral TMP-SMX (TMP 480 mg/day and SMX 2,400 mg/day) administration. However, the fever continued to rise daily and CRP remained elevated for 5 days after the initial treatment. Therefore, in vitro susceptibility tests were performed in the N. otitidiscaviarum by using the disk method (KB disk, Eiken Chemical CO., Ltd., Tokyo, Japan). As a result, the organism was resistant to IPM/CS, MINO, ampicillin, piperacillin sodium, cefotiam hydrochloride, vancomycin hydrochloride, but susceptible to LVFX and GM (Table 3) . Susceptibility to TMP-SMX and erythromycin was intermediate. According to the susceptibility tests, LVFX (300 mg/ day, oral) and GM (120 mg/day, intravenous) were added to TMP-SMX (TMP 480 mg/day and SMX 2,400 mg/day, oral) and administered to the patient. Three days after changing the treatment, this combination therapy resulted in abatement of fever and improvement in chest symptoms. His hyperglycemia was effectively treated with insulin therapy throughout the clinical course. Over the next three weeks, CRP also decreased gradually and the patient was discharged from the hospital. Figure 3 shows the clinical course. Using LVFX (300 mg/day for 3 month) and TMP-SMX (TMP 240 mg/day and SMX 1,200 mg/day for 6 months), the patient remained asymptomatic for the next six months. There was no recurrence for more than 2 years of observation.
Discussion
Nocardiosis is a well-described infection in immunocompromised patients such as those with cancer, organ transplants and immunosuppressive therapy (1). Suppression of cell-mediated immune response, particularly macrophages and T cells, plays an important role in the establishment of nocardiosis (7). Glucocorticoid is well recognized and widely used for immune suppression, and it is one of the great risk factors for invasive nocardiosis (6, 8) . In the present case, prolonged corticosteroid administration, the hyperglycemic state and having rheumatoid vasculitis were considered to be the major contributors to his impaired immunity. Recently, Hui et al have retrospectively reviewed 35 patients with pulmonary nocardiosis (6) . They reported that the majority (63%) of them had an underlying respiratory disorder ranging from common conditions such as chronic obstructive lung disease (26%), asthma and bronchiectasis (20%) to less common ones such as previous tuberculosis and cystic fibrosis (5.7%). Non-respiratory disorders were comprised of patients with underlying malignancies (20%), organ transplantation (8.6%), autoimmune disorders (5.7%), and HIV (5.7%). Among all patients, 21 (60%) were receiving corticosteroids and/or other forms of immunosuppressive therapy. (9) . The most common organism that causes pulmonary nocardiosis is N. asteroids. N. otitidiscaviarum is rarely isolated in nontropical countries. Most other cases of N. otitidiscaviarum infection have not been well documented (10) . To our knowledge, there are few reported cases of pulmonary N. otitidiscaviarum infection (6, 11) . In addition, the present case is the first report of pyothorax caused by N. otitidiscaviarum. It is difficult to isolate the Nocardia species since less than 30% of pulmonary nocardiosis is diagnosed by sputum cultures (12) . In the present case, we could successfully isolate the pathogen in the pleural fluid.
Nocardiosis is usually treated initially with TMP-SMX (6, 13) . Recent in vitro studies have shown the usefulness of other drugs, such as MINO, IPM/CS, third generation cephalosporins, and aminoglycosides (14) . There are some reported cases of pulmonary nocardiosis that respond to imipenem alone (15) . Unlike N. asteroids, which has a variable pattern of antibiotic resistance, N. otitidiscaviarum displays more predictable results with regard to susceptibility to antibiotics (16) . However, we changed the therapy after isolation of N. otitidiscaviarum because of the clinical course and susceptibility tests indicated no effectiveness of IPM/CS and MINO. LVFX and GM was susceptible and achieved successful treatment. Taniguchi et al have reported a similar case with pulmonary N. otitidiscaviarum infection that had resistance to IPM/CS and MINO (11) . Their case improved after treatment with TMP-SMX which was selected by susceptibility tests. It is noteworthy that delayed diagnosis and inappropriate therapy may result in fatal outcome. Therefore, it is important to recognize the disease itself, especially in immunocompromised patients and prompt initiation of the appropriate treatment based on isolation of the pathogen followed by susceptibility tests is critical.
The optimal duration of therapy for N. otitidiscaviarum infection, as with other types of Nocardial infections, is unknown (10) . In general, the duration of treatment of nocardiosis is recommended to be from 6 weeks for limited infection to more than 12 months for a severe disease (17) . Wallace et al reported that relapse is rare in patients treated for more than 3 months (18) . In the present case, there was treatment of LVFX for 3 months and TMP-SMX for 6 months. There was no recurrence or side effects seen for more than 24 months of follow-up. Further studies with N. otitidiscaviarum are needed to evaluate the correlation between the Nocardia species, drug susceptibility, and clinical outcome. 
